Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Kausik Ray, MBChB, MD, MPhil
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Prof. Christoph Wanner
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Bridging ASCVD Care Between Academic and Rural Settings
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
NYHA FC and Finerenone Response: Clinical Trial Insights
John Ostrominski
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.